Dr. Sara M. Tolaney, MD
Hematology & Oncology (Hematology & Oncology Physician)
55 Fruit Street Yaw 7604, Massachusetts General Hospital
Boston, MA 02114
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 37
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of California, San Francisco School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 223936 -
Internal Medicine Physician
MA license 223936
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 37
- Services billed
- 104
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 92 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Verzenio (abemaciclib) | 14 |
| Letrozole Other prescribers in Boston, MA | 14 |
| Ibrance (palbociclib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 114 payments worth $177,137 in total to this clinician.
| F. Hoffmann-la Roche AG | $29,218 |
|---|---|
| Gilead Sciences, Inc. | $24,349 |
| Pfizer Inc. | $21,703 |
| Eli Lilly and Company | $18,138 |
| AstraZeneca UK Limited | $16,003 |
| E.r. Squibb & Sons, L.l.c. | $15,816 |
| Daiichi Sankyo Inc. | $9,608 |
| Beigene USA, Inc. | $8,000 |
| Consulting Fee | $149,360 |
|---|---|
| Travel and Lodging | $16,347 |
| Compensation for services other than consulting (speaking, faculty) | $9,135 |
| Food and Beverage | $2,251 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 2, 2025 | Consulting Fee | $14,067 |
| Gilead Sciences, Inc. Jul 2, 2025 | Consulting FeeCompany’s description;4200483;GTF;11313049 | $13,750 |
| F. Hoffmann-la Roche AG May 14, 2025 | Travel and Lodging Kadcyla; Perjeta · BioOncology · travel to Munich, Germany | $9,866 |
| Beigene USA, Inc. Mar 4, 2025 | Consulting Fee | $8,000 |
| Eli Lilly and Company Mar 19, 2025 | Consulting Fee | $6,500 |
| AstraZeneca UK Limited Jun 6, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,150 |
| F. Hoffmann-la Roche AG May 14, 2025 | Consulting Fee Kadcyla; Perjeta · BioOncology | $6,150 |
| Pfizer Inc. Nov 17, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $4,800 |
| Eli Lilly and Company Dec 18, 2025 | Consulting Fee | $4,600 |
| Boehringer Ingelheim International GmbH Jul 9, 2025 | Consulting Fee | $4,255 |
All 77 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Dec 22, 2025 | Consulting Fee | $1,600 |
| Eli Lilly and Company Dec 18, 2025 | Consulting Fee | $4,600 |
| Corcept Therapeutics Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,000 |
| AstraZeneca UK Limited Dec 16, 2025 | Consulting Fee ENHERTU · Oncology Company’s descriptionResearch Related Service | $833 |
| E.r. Squibb & Sons, L.l.c. Dec 12, 2025 | Consulting Fee | $1,290 |
| Pfizer Inc. Dec 11, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $3,200 |
| Pfizer Inc. Dec 11, 2025 | Consulting Fee | $1,540 |
| Pfizer Inc. Dec 11, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $800 |
| Pfizer Inc. Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) TUKYSA · ONCOLOGY | $1,855 |
| Merck Sharp & Dohme LLC Dec 8, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a research engagement. | $320 |
| AstraZeneca UK Limited Dec 3, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,028 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a research engagement. | $960 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Pfizer Inc. Nov 17, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $4,800 |
| Pfizer Inc. Nov 17, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $1,500 |
| Daiichi Sankyo Inc. Nov 12, 2025 | Consulting Fee Enhertu · ONCOLOGY | $1,370 |
| Daiichi Sankyo Inc. Nov 12, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,250 |
| Daiichi Sankyo Inc. Nov 12, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $343 |
| AstraZeneca UK Limited Nov 10, 2025 | Travel and Lodging travel to Berlin, Germany Company’s descriptionResearch Related Service | $99.87 |
| E.r. Squibb & Sons, L.l.c. Nov 7, 2025 | Travel and Lodging travel to BOSTON, MA | $85.51 |
| Daiichi Sankyo Inc. Nov 5, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,370 |
| AstraZeneca UK Limited Oct 31, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $685 |
| F. Hoffmann-la Roche AG Oct 20, 2025 | Consulting Fee Perjeta · BioOncology | $1,230 |
| Gilead Sciences, Inc. Oct 18, 2025 | Travel and Lodging Trodelvy · ONC · travel to Foster City, CA · in-kind Company’s description;4253427;VEM US;11313049 | $634 |
| AstraZeneca Pharmaceuticals LP Oct 17, 2025 | Consulting Fee Truqap · Oncology | $2,460 |
| Jazz Pharmaceuticals Inc. Oct 9, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $1,674 |
| Daiichi Sankyo Inc. Oct 8, 2025 | Consulting Fee Enhertu · ONCOLOGY | $1,370 |
| E.r. Squibb & Sons, L.l.c. Oct 2, 2025 | Consulting Fee | $14,067 |
| Eli Lilly and Company Sep 23, 2025 | Consulting Fee | $900 |
| Genentech, Inc. Sep 22, 2025 | Consulting Fee | $1,640 |
| Gilead Sciences, Inc. Sep 11, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4147842;VEM US;11313049 | $2,480 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $37.74 |
| Novartis Pharma AG Aug 5, 2025 | Consulting Fee KISQALI · Oncology | $3,545 |
| Eli Lilly and Company Jul 31, 2025 | Consulting Fee VERZENIO · Oncology | $1,800 |
| Samsung Bioepis Co., LTD. Jul 31, 2025 | Consulting Fee E303 · Hematology & Oncology | $520 |
| Merck Sharp & Dohme LLC Jul 30, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $640 |
| Stemline Therapeutics Inc. Jul 25, 2025 | Consulting Fee Orserdu · Oncology | $390 |
| Gilead Sciences, Inc. Jul 16, 2025 | Consulting FeeCompany’s description;4280026;GTF;11313049 | $3,810 |
| Boehringer Ingelheim International GmbH Jul 9, 2025 | Consulting Fee | $4,255 |
| Gilead Sciences, Inc. Jul 2, 2025 | Consulting FeeCompany’s description;4200483;GTF;11313049 | $13,750 |
| F. Hoffmann-la Roche AG Jul 1, 2025 | Consulting Fee Herceptin; Kadcyla; Perjeta · BioOncology | $1,520 |
| AstraZeneca UK Limited Jul 1, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $833 |
| AstraZeneca UK Limited Jun 25, 2025 | Travel and Lodging travel to chicago, IL Company’s descriptionResearch Related Service | $210 |
| AstraZeneca UK Limited Jun 25, 2025 | Travel and Lodging travel to chicago, IL Company’s descriptionResearch Related Service | $82.71 |
| Pfizer Inc. Jun 20, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $1,800 |
| F. Hoffmann-la Roche AG Jun 19, 2025 | Consulting Fee Kadcyla; Perjeta · BioOncology | $3,280 |
| AstraZeneca UK Limited Jun 6, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,150 |
| F. Hoffmann-la Roche AG Jun 6, 2025 | Consulting Fee Perjeta · BioOncology | $2,870 |
| Gilead Sciences, Inc. May 29, 2025 | Travel and Lodging travel to Chicago, IL Company’s description;4280047;GTF;11313049 | $270 |
| Gilead Sciences, Inc. May 29, 2025 | Travel and Lodging travel to Chicago, IL Company’s description;4280039;GTF;11313049 | $105 |
| Daiichi Sankyo Inc. May 28, 2025 | Consulting Fee Enhertu · ONCOLOGY | $2,055 |
| F. Hoffmann-la Roche AG May 14, 2025 | Travel and Lodging Kadcyla; Perjeta · BioOncology · travel to Munich, Germany | $9,866 |
| F. Hoffmann-la Roche AG May 14, 2025 | Consulting Fee Kadcyla; Perjeta · BioOncology | $6,150 |
| F. Hoffmann-la Roche AG May 14, 2025 | Compensation for services other than consulting (speaking, faculty) Kadcyla · BioOncology | $3,280 |
| Daiichi Sankyo Inc. May 14, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,563 |
| F. Hoffmann-la Roche AG May 14, 2025 | Travel and Lodging Kadcyla; Perjeta · BioOncology · travel to Munich, Germany | $446 |
| F. Hoffmann-la Roche AG May 14, 2025 | Travel and Lodging Kadcyla; Perjeta · BioOncology · travel to Munich, Germany | $178 |
| AstraZeneca UK Limited May 7, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $649 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee | $2,880 |
| Eli Lilly and Company Apr 18, 2025 | Travel and Lodging travel to VIENNA, Austria | $4,236 |
| Eli Lilly and Company Apr 18, 2025 | Travel and Lodging travel to VIENNA, Austria | $72.12 |
| Eli Lilly and Company Apr 18, 2025 | Travel and Lodging travel to VIENNA, Austria | $25.00 |
| F. Hoffmann-la Roche AG Apr 1, 2025 | Consulting Fee Herceptin; Kadcyla; Perjeta · BioOncology | $380 |
| Eli Lilly and Company Mar 19, 2025 | Consulting Fee | $6,500 |
| Stemline Therapeutics Inc. Mar 14, 2025 | Consulting Fee Orserdu · Oncology | $780 |
| AstraZeneca UK Limited Mar 7, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,100 |
| Novartis Pharmaceuticals Corporation Mar 7, 2025 | Consulting Fee KISQALI · Oncology | $2,550 |
| Beigene USA, Inc. Mar 4, 2025 | Consulting Fee | $8,000 |
| AstraZeneca Pharmaceuticals LP Mar 2, 2025 | Consulting Fee ENHERTU · Oncology | $2,226 |
| Gilead Sciences, Inc. Feb 19, 2025 | Consulting Fee Trodelvy · ONC Company’s description;3907981;SAP;11313049 | $2,910 |
| Pfizer Inc. Feb 14, 2025 | Consulting Fee | $600 |
| Merck Sharp & Dohme LLC Feb 12, 2025 | Consulting Fee | $2,240 |
| AstraZeneca UK Limited Feb 3, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $343 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $915 |
| Pfizer Inc. Jan 13, 2025 | Consulting Fee | $4,234 |
| Pfizer Inc. Jan 7, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,260 |
| AstraZeneca UK Limited Jan 6, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $555 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 9 companies. The companies reported $3,018,300 in research payments for these studies, mostly to the institutions running them.
- ATEMPT 2 0
Genentech, Inc. - A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
Pfizer Inc. - A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca Pharmaceuticals LP - An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastati…
Merck Sharp & Dohme LLC - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc. - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - A phase 3, open-label, randomized study of dato-dxd versus investigators choice of chemotherapy in participants with inoperable or metastatic hormone receptor positive, HER2 negative breast cancer who have been treate…
AstraZeneca Pharmaceuticals LP - The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.